Global Statistics

All countries
240,188,856
Confirmed
Updated on October 14, 2021 1:43 pm
All countries
215,765,598
Recovered
Updated on October 14, 2021 1:43 pm
All countries
4,893,161
Deaths
Updated on October 14, 2021 1:43 pm
Saturday, October 16, 2021

Global Statistics

All countries
240,188,856
Confirmed
Updated on October 14, 2021 1:43 pm
All countries
215,765,598
Recovered
Updated on October 14, 2021 1:43 pm
All countries
4,893,161
Deaths
Updated on October 14, 2021 1:43 pm
Molderizer and Safe Shield

Bharat Biotech’s Covaxin gets expert panel’s nod for children above 2 years

420,000 homeless students went missing from schools’ rolls

ST. GEORGE, Utah — A week before school started in this sunny desert city, Mike Carr waited at the front desk of the...

Maharashtra: Man Dies On Doorstep Of Hospital After He Was Denied For Oxygen | India Today

With the rise in COVID-19 cases in Maharashtra, another distressing news has surfaced from the state. A man died on the doorstep of hospital...

Coronavirus Vaccine Latest Updates | Aaj Ki Taaza Khabar

Coronavirus Vaccine Latest Updates | Aaj Ki Taaza Khabar #CoronaVaccine #ImranKhan #BOLNews. source

Coronavirus in Russia: The Latest News | Oct. 16

Russia has confirmed 7,958,384 cases of coronavirus and 222,315 deaths, according to...

North Texas Man Charged for Threatening Maryland Doctor for COVID-19 Vaccine Advocacy

A North Texas man who allegedly threatened a prominent doctor over her support for COVID-19 vaccines has been charged in federal court, officials...




Bharat Biotech’s Covaxin will become the world’s first Covid-19 approved for use in as young as 2 years. The expert panel advising India’s drug regulator on Tuesday recommended granting emergency use authorisation to the for in the 2-18 years age group.


The Hyderabad-based company has been asked to submit data on any adverse event following every 15 days for the next two months. It has also been told to update the package inserts, fact sheet, and summary of product characteristics for its pack.


said it was awaiting further regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) before the company could launch the product for The Subject Expert Committee (SEC) has submitted its recommendation to the drug regulator, and a formal approval from the Drugs Controller General of India (DCGI) is expected after he examines the data and the recommendation.


has submitted data from clinical trials in the 2-18 years’ age group for Covaxin (BBV152) to the CDSCO. The data has been thoroughly reviewed by the CDSCO and SEC, and they have provided their positive recommendations,” the company said. The firm had submitted data from its paediatric trials to the regulator last week.


The gap between the two doses of Covaxin will be 28 days, as in the case of adults, the company said. Sources in the company confirmed that the vaccine for children was the same drug substance as Covaxin.


“This represents one of the first approvals worldwide for Covid-19 vaccines for the 2-18 age groups,” the company said.


ALSO READ: WHO technical advisory group to take call on Covaxin EUL next week






The SEC has asked to continue the study according to the whole-virion inactivated vaccine-approved clinical trial protocol. The company has also been asked to submit safety data, including data on adverse events following immunisation (AEFI) and adverse event of special interest (AESI) every 15 days for the first two months, and thereafter on a monthly basis. The firm should submit a risk management plan according to the New Drugs & Clinical Trials Rules, 2019.


A Mumbai-based analyst said, “It is estimated that 350-400 million people in India are below the age of 18 years. A two-dose Covid vaccine regimen would translate into 700-800 million doses of potential demand.”


Bharat Biotech has struggled to keep pace with demand for its Covid-19 shots. The company has indicated it would make 55 million doses in October and is aiming to touch 80 million doses a month by December.


As of now, the other vaccines approved for children so far are for use in three years and above.


chart


Serum Institute of India is conducting trials on children aged 7 years and above for US major Novavax’s Covid-19 vaccine (Covovax) here. The next leg of Covovax trials will include children aged 2 years and above. The permission from the regulator is coming in phases. Zydus Cadila’s DNA vaccine has been approved for adolescents 12 years and above. The three-dose product is yet to be made available in the market. This would make Covaxin the first paediatric product available in India.


Clinicians felt that vaccine hesitancy would not be a problem for the paediatric vaccine.


“The vaccine efficacy has been found to be similar to what was observed in adults. More importantly, the vaccine is extremely safe. With the WHO’s approval expected in a week, which will also be a welcome progress, we could see the beginning of the last leg of the fight against Covid-19,” said Dr Trupti Gilada, infectious disease specialist at Masina Hospital, Mumbai. She added that vaccine hesitancy observed during the initial phases was something that shouldn’t be observed for children because India has had a very successful children immunisation tradition.


Globally, Sinovac had said its vaccine was safe for use in children aged 3 years and above. In September, Chile approved it for children aged 6 years and older. The Pfizer and Moderna mRNA vaccines have been used for adolescents.


Around June 2021, some cases of myocarditis (inflammation of heart walls) were reported in the US after taking the Pfizer-BioNTech vaccine, primarily among young males after they got the second shot. The US Centers for Disease Control and Prevention’s advisory committee on immunisation practices reviewed available data and concluded that the benefits of Covid-19 to individual persons and the population outweigh the risks for myocarditis and recommended continued use of the vaccine in persons aged 12 years and above.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

420,000 homeless students went missing from schools’ rolls

ST. GEORGE, Utah — A week before school started in this sunny desert city, Mike Carr waited at the front desk of the...

Maharashtra: Man Dies On Doorstep Of Hospital After He Was Denied For Oxygen | India Today

With the rise in COVID-19 cases in Maharashtra, another distressing news has surfaced from the state. A man died on the doorstep of hospital...

Coronavirus Vaccine Latest Updates | Aaj Ki Taaza Khabar

Coronavirus Vaccine Latest Updates | Aaj Ki Taaza Khabar #CoronaVaccine #ImranKhan #BOLNews. source

Related Articles

420,000 homeless students went missing from schools’ rolls

ST. GEORGE, Utah — A week before school started in this sunny desert city, Mike Carr waited at the front desk of the...

Maharashtra: Man Dies On Doorstep Of Hospital After He Was Denied For Oxygen | India Today

With the rise in COVID-19 cases in Maharashtra, another distressing news has surfaced from the state. A man died on the doorstep of hospital...

Coronavirus Vaccine Latest Updates | Aaj Ki Taaza Khabar

Coronavirus Vaccine Latest Updates | Aaj Ki Taaza Khabar #CoronaVaccine #ImranKhan #BOLNews. source